



The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Please note that the results reported in any single trial may not reflect the overall potential risks or benefits of a product which are based on an evaluation of an entire research program.

Before prescribing any Takeda products, healthcare professionals should consult prescribing information for the product approved in their country.

Ferumoxytol-5005 Results Synopsis

In both the 2010 and 2011 data, unadjusted hypersensitivity/hypotension event rates and mortality rates were higher for patients using Feraheme than for patients using Venofer or Ferrlecit, however in the 2011 analysis there were overlapping confidence intervals (CIs) for the analysis of hypersensitivity/hypotension events. In the non-dialysis CKD population, unadjusted hypersensitivity/hypotension rates were higher, but mortality rates were lower for patients using Feraheme than for patients using Venofer or Ferrlecit, with overlapping CIs.

This was a crude and descriptive analysis which did not adjust for patient characteristics, comorbid conditions, or history of hypersensitivity; therefore comparisons between the IV iron types without considering potential differences in user populations should be made with caution. A potential source of bias is the possibility that Feraheme could have been disproportionately given to patients with a prior history of reactions to iron. The study was further limited by the fact that this was an analysis at the event level, and intra-patient correlation of event occurrence was not accounted for.